Treatment	treatment	O	O
of	of	O	O
ifosfamide-induced	ifosfamide-induced	O	O
urothelial	urothelial	O	O
toxicity	toxicity	O	O
by	by	O	O
oral	oral	O	O
administration	administration	O	O
of	of	O	O
sodium	sodium	S_chemicals	O
2-mercaptoethane	2-mercaptoethane	O	O
sulphonate	sulphonate	O	O
(	(	O	O
MESNA	mesna	S_chemicals	O
)	)	O	O
to	to	O	O
patients	patients	O	O
with	with	O	O
inoperable	inoperable	O	O
lung	lung	O	B_disease
cancer	cancer	O	S_disease
.	.	O	O

The	the	O	O
protective	protective	O	O
effect	effect	O	O
of	of	O	O
oral	oral	O	O
administration	administration	O	O
of	of	O	O
the	the	O	O
thiol	thiol	S_chemicals	O
compound	compound	O	O
sodium	sodium	S_chemicals	O
2-mercaptoethane	2-mercaptoethane	O	O
sulphonate	sulphonate	O	O
(	(	O	O
MESNA	mesna	S_chemicals	O
)	)	O	O
against	against	O	O
urothelial	urothelial	O	O
toxicity	toxicity	O	O
induced	induced	O	O
by	by	O	O
ifosfamide	ifosfamide	S_chemicals	O
(	(	O	O
IF	if	O	O
)	)	O	O
was	was	O	O
tested	tested	O	O
in	in	O	O
a	a	O	O
group	group	O	O
of	of	O	O
45	45	O	O
patients	patients	O	O
with	with	O	O
inoperable	inoperable	O	O
lung	lung	O	B_disease
cancer	cancer	O	S_disease
under	under	O	O
treatment	treatment	O	O
with	with	O	O
IF	if	O	O
(	(	O	O
2250	2250	O	O
mg/m2	mg/m2	O	O
on	on	O	O
days	days	O	O
2	2	O	O
-	-	O	O
5	5	O	O
)	)	O	O
as	as	O	O
part	part	O	O
of	of	O	O
a	a	O	O
polychemotherapy	polychemotherapy	O	O
regimen	regimen	O	O
repeated	repeated	O	O
in	in	O	O
a	a	O	O
4-week	4-week	O	O
cycle	cycle	O	O
.	.	O	O

MESNA	mesna	S_chemicals	O
was	was	O	O
given	given	O	O
orally	orally	O	O
on	on	O	O
the	the	O	O
days	days	O	O
of	of	O	O
treatment	treatment	O	O
with	with	O	O
IF	if	O	O
in	in	O	O
3	3	O	O
doses	doses	O	O
of	of	O	O
840	840	O	O
mg/m2	mg/m2	O	O
,	,	O	O
each	each	O	O
administered	administered	O	O
at	at	O	O
0	0	O	O
hr	hr	O	O
(=	(=	O	O
injection	injection	O	O
of	of	O	O
IF	if	O	O
)	)	O	O
,	,	O	O
4	4	O	O
hr	hr	O	O
and	and	O	O
8	8	O	O
hr	hr	O	O
p.i	p.i	O	O
.	.	O	O

Out	out	O	O
of	of	O	O
a	a	O	O
total	total	O	O
of	of	O	O
88	88	O	O
courses	courses	O	O
of	of	O	O
this	this	O	O
treatment	treatment	O	O
we	we	O	O
observed	observed	O	O
10	10	O	O
episodes	episodes	O	O
of	of	O	O
asymptomatic	asymptomatic	O	O
microscopic	microscopic	O	O
haematuria	haematuria	O	O
and	and	O	O
no	no	O	O
episodes	episodes	O	O
of	of	O	O
gross	gross	O	O
haematuria	haematuria	O	O
.	.	O	O

In	in	O	O
this	this	O	O
group	group	O	O
of	of	O	O
45	45	O	O
patients	patients	O	O
under	under	O	O
protection	protection	O	O
with	with	O	O
MESNA	mesna	S_chemicals	O
there	there	O	O
were	were	O	O
5	5	O	O
complete	complete	O	O
remissions	remissions	O	O
and	and	O	O
9	9	O	O
partial	partial	O	O
remissions	remissions	O	O
(	(	O	O
total	total	O	O
31	31	O	O
%	%	O	O
)	)	O	O
.	.	O	O

A	a	O	O
further	further	O	O
group	group	O	O
of	of	O	O
25	25	O	O
patients	patients	O	O
under	under	O	O
polychemotherapy	polychemotherapy	O	O
with	with	O	O
IF	if	O	O
were	were	O	O
treated	treated	O	O
by	by	O	O
conventional	conventional	O	O
prophylactic	prophylactic	O	O
measures	measures	O	O
(	(	O	O
raised	raised	O	O
fluid	fluid	O	O
intake	intake	O	O
and	and	O	O
forced	forced	O	O
diuresis	diuresis	O	O
)	)	O	O
.	.	O	O

In	in	O	O
this	this	O	O
group	group	O	O
there	there	O	O
were	were	O	O
1	1	O	O
complete	complete	O	O
and	and	O	O
5	5	O	O
partial	partial	O	O
remissions	remissions	O	O
(	(	O	O
total	total	O	O
24	24	O	O
%	%	O	O
)	)	O	O
,	,	O	O
but	but	O	O
nearly	nearly	O	O
all	all	O	O
patients	patients	O	O
developed	developed	O	O
either	either	O	O
gross	gross	O	O
haematuria	haematuria	O	O
and/or	and/or	O	O
symptoms	symptoms	O	O
of	of	O	O
bladder	bladder	O	O
irritation	irritation	O	S_disease
(	(	O	O
cystitis	cystitis	O	S_disease
and	and	O	O
pollakisuria	pollakisuria	O	O
)	)	O	O
.	.	O	O

There	there	O	O
were	were	O	O
no	no	O	O
appreciable	appreciable	O	O
differences	differences	O	O
between	between	O	O
the	the	O	O
MESNA	mesna	S_chemicals	O
series	series	O	O
and	and	O	O
the	the	O	O
conventional	conventional	O	O
prophylaxis	prophylaxis	O	O
series	series	O	O
with	with	O	O
respect	respect	O	O
to	to	O	O
either	either	O	O
haematological	haematological	O	O
or	or	O	O
systemic	systemic	O	O
toxicity	toxicity	O	O
of	of	O	O
the	the	O	O
cytostatic	cytostatic	S_chemicals	O
treatment	treatment	O	O
.	.	O	O

Our	our	O	O
results	results	O	O
support	support	O	O
the	the	O	O
view	view	O	O
that	that	O	O
MESNA	mesna	S_chemicals	O
,	,	O	O
given	given	O	O
orally	orally	O	O
in	in	O	O
conjunction	conjunction	O	O
with	with	O	O
combined	combined	O	O
cytostatic	cytostatic	S_chemicals	O
regimens	regimens	O	O
which	which	O	O
include	include	O	O
IF	if	O	O
,	,	O	O
simplifies	simplifies	O	O
the	the	O	O
treatment	treatment	O	O
and	and	O	O
provides	provides	O	O
optimum	optimum	O	O
protection	protection	O	O
for	for	O	O
the	the	O	O
urinary	urinary	O	O
epithelium	epithelium	O	O
.	.	O	O

Protection	protection	O	O
with	with	O	O
oral	oral	O	O
MESNA	mesna	S_chemicals	O
is	is	O	O
particularly	particularly	O	O
suitable	suitable	O	O
for	for	O	O
outpatients	outpatients	O	O
.	.	O	O

